Genetic-specific therapies gain insurers' acceptance
28th Nov 2005, 05:30 GMT
Increased knowledge of how genes affect certain types of cancer has created drugs designed to target those specific genes.
Genetic-specific therapies gain insurers' acceptance related news:
- Ontogeny of Additive and Maternal Genetic Effects: Lessons from Domestic Mammals — Am Nat Latest Articles
- More tailored therapy for kids' cancers? — United Press International - Health Business
- Medicare's Fine Print — washingtonpost.com - Letters to the Editor
- New York Times Examines Debate Over Preimplantation Genetic Diagnosis — Medical News Today RSS/XML Feed
- Center calls for stronger federal regulation of genetic testing — EurekAlert! - Breaking News
- Ban furor now up in smoke; three years after taking effect, limits gain acceptance. — Environmental Health News
- Powering Up a New Broadband Option — TechNewsWorld
- Mild weather boosts Japan's insurers — WSJ.com: What's News Asia
- Grasping the essentials — Nature Signaling Update
- Insurers slam Turner's state savings plan — Scotsman.com News - Pensions
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- Spectrum Pharmaceuticals gets $5M milestone payment, settles with GlaxoSmithKline
- Corautus Genetics chips at Q3 loss
- Spherix hoping to brush its sweet tooth
- Auxilium added to NASDAQ's biotech index
- CombinatoRx reports revenue boost
- Alexion gets fast-track FDA review for drug Soliris
- InnoCentive identifies a new CEO
- Digene names new CEO
- Dynamic Health dips into the red
- Sigma-Aldrich elects Paul to board